333 related articles for article (PubMed ID: 21064013)
1. [Novel anticoagulants for stroke prevention in atrial fibrillation].
Baumhäkel M; Schirmer SH; Böhm M
Dtsch Med Wochenschr; 2010 Nov; 135(46):2304-8. PubMed ID: 21064013
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants in non-valvular atrial fibrillation.
Potpara TS; Lip GY
Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
[TBL] [Abstract][Full Text] [Related]
6. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
7. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic treatment of atrial fibrillation: new insights.
Le Heuzey JY
Thromb Res; 2012 Oct; 130 Suppl 1():S59-60. PubMed ID: 23026665
[TBL] [Abstract][Full Text] [Related]
9. Apixaban for the prevention of stroke in atrial fibrillation.
Littrell R; Flaker G
Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
[TBL] [Abstract][Full Text] [Related]
10. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Morales-Vidal S; Schneck MJ; Flaster M; Biller J
Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673
[TBL] [Abstract][Full Text] [Related]
11. [Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].
Geisler T; Gawaz M
MMW Fortschr Med; 2011 Apr; 153(15):27-30; quiz 31. PubMed ID: 21667556
[No Abstract] [Full Text] [Related]
12. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Ahrens I; Lip GY; Peter K
Thromb Haemost; 2011 Apr; 105(4):574-8. PubMed ID: 21225102
[No Abstract] [Full Text] [Related]
13. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
14. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Kasmeridis C; Lip GY; Apostolakis S
Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
[TBL] [Abstract][Full Text] [Related]
15. Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
Toth PP
Postgrad Med; 2013 May; 125(3):155-61. PubMed ID: 23748516
[TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Contractor T; Levin V; Martinez MW; Marchlinski FE
Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
[TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants in elderly patients.
Barco S; Cheung YW; Eikelboom JW; Coppens M
Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
[TBL] [Abstract][Full Text] [Related]
18. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Galanis T; Merli GJ
Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965
[TBL] [Abstract][Full Text] [Related]
19. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
20. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Harenberg J; Wehling M
Semin Thromb Hemost; 2008 Feb; 34(1):39-57. PubMed ID: 18393142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
